1. Home
  2. CHE

as of 08-21-2026 3:45pm EST

$541.54
+$6.66
+1.25%
Stocks Health Care Medical/Nursing Services Nasdaq

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

Founded: 1970 Country:
United States
United States
Employees: N/A City: CINCINNATI
Market Cap: 6.1B IPO Year: 1994
Target Price: $501.50 AVG Volume (30 days): 148.0K
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield:
0.57%
Dividend Payout Frequency: quarterly
EPS: 9.97 EPS Growth: -7.79
52 Week Low/High: $365.20 - $557.00 Next Earning Date: 04-23-2026
Revenue: $2,529,978,000 Revenue Growth: 4.06%
Revenue Growth (this year): 6.56% Revenue Growth (next year): 6.23%
P/E Ratio: 53.65 Index: N/A
Free Cash Flow: 325.5M FCF Growth: +19.70%

Stock Insider Trading Activity of Chemed Corp (CHE)

MCNAMARA KEVIN J

president and CEO

Sell
CHE Aug 3, 2026

Avg Cost/Share

$539.51

Shares

2,000

Total Value

$1,079,020.00

Owned After

70,418

SEC Form 4

Sell
CHE Jul 31, 2026

Avg Cost/Share

$532.00

Shares

190

Total Value

$101,080.00

Owned After

3,533

SEC Form 4

Sell
CHE Jun 9, 2026

Avg Cost/Share

$447.33

Shares

1,347

Total Value

$602,553.51

Owned After

4,578

SEC Form 4

Sell
CHE May 29, 2026

Avg Cost/Share

$437.83

Shares

500

Total Value

$218,915.00

Owned After

3,209

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q2

Q2 2026 Earnings

8-K SELL

Jul 28, 2026 · 100% conf.

AI Prediction SELL

1D

-7.18%

$480.48

Act: +4.20%

5D

-6.75%

$482.67

20D

-7.22%

$480.28

Price: $517.63 Prob +5D: 0% AUC: 1.000
0000019584-26-000018

EX-99

2 che-20260728xex99.htm

EX-99

Exhibit 99

CONTACT:  Michael D. Witzeman

(513) 762-6714

Chemed Reports Second-Quarter 2026 Results

Full-Year Guidance Increased Due Mainly to VITAS Outperformance

CINCINNATI, July 28, 2026—Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS),  the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2026, versus the comparable prior-year period.

Results for Quarter Ended June 30, 2026

Consolidated operating results:

·

Revenue increased 8.8% to $673.3 million

·

GAAP Diluted Earnings-per-Share (EPS) of $5.13, an increase of 43.7%

·

Adjusted Diluted EPS of $6.06, an increase of 41.9%

VITAS segment operating results:

·

Net Patient Revenue of $443.3 million, an increase of 11.9%

·

Average Daily Census (ADC) of 23,687, an increase of 6.1%

·

Admissions of 19,125, an increase of 9.0%

·

Net Income, excluding certain discrete items, of $61.3 million, an increase of 60.5%

·

Adjusted EBITDA, excluding Medicare Cap, of $80.6 million, an increase of 20.6%

·

Adjusted EBITDA margin, excluding Medicare Cap, of 18.2%, an increase of 196-basis points

Roto-Rooter segment operating results:

·

Revenue of $229.9 million, an increase of 3.3%

·

Net Income, excluding certain discrete items, of $33.8 million, essentially flat

·

Adjusted EBITDA of $48.5 million, essentially flat

·

Adjusted EBITDA margin of 21.1%, a decline of 77-basis points

VITAS

VITAS net revenue was $443.3 million in the second quarter of 2026, which is an increase of 11.9% when compared to the prior-year period. This revenue increase is comprised primarily of a 6.1% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.4%. Acuity mix shift negatively impacted revenue growth 115-basis points in the quarter when compared to the prior-year period’s revenue and level-of-care mix.  The combination of Medicare Cap and other contra revenue changes positively impacted revenue growth by 455-basis points.

Total VITAS admissions increased 9.0% in the second quarter of 2026 compared to the second quarter of 2025.

In the second quarter of 2026, VITAS accrued $500,000 in Medicare Cap billing limitation.  This compares to the Medicare Cap billing limitation recorded in the second quarter of 2025 of $16.4 million.  No Medicare Cap billing limitation was recorded in the second quarter of 2026 for the Florida combined program, and none is anticipated for the 2026 fiscal period.

Of VITAS’ 33 Medicare provider numbers, 22 provider numbers have an anticipated full-year Medicare Cap cushion of 10% or greater, seven provider numbers have a cushion between 0% and 10%, and four provider numbers have a Medicare Cap billing limitation totaling $7.0 million.

Average revenue per patient per day in the second quarter of 2026 was $209.98 which is 143-basis points above the prior-year period. Reimbursement for routine home care and high-acuity care averaged $188.62 and $1,152.14, respectively. During the quarter, high-acuity days-of-care were 2.2% of total days of care, a decline of 24-basis points when compared to the prior-year quarter.

The second quarter 2026 gross margin, excluding Medicare Cap, was 23.9%, a 164-basis point increase from the same period of 2025. Selling, general and administrative expenses were $26.1 million in the second quarter of 2026 compared to $25.1 million in the prior- year quarter.

Adjusted EBITDA, excluding Medicare Cap, totaled $80.6 million in the quarter, an increase of 20.6% when compared to the prior-year period. Adjusted EBITDA margin in the quarter, excluding Medicare Cap, was 18.2%.

Roto-Rooter

Roto-Rooter generated quarterly revenue of $229.9 million in the second quarter of 2026, an increase of 3.3%, when compared to the prior-year quarter.

Roto-Rooter branch commercial revenue in the quarter totaled $56.8 million, an increase of 6.8% from the prior-year period. This aggregate commercial revenue change consisted of plumbing increasing 11.9%, drain cleaning increasing 6.9%, water restoration increasing 3.7% and excavation increasing 2.3%.

Roto-Rooter branch residential revenue in the quarter totaled $159.1 million, an increase of 1.7%, over the prior-year period. This aggregate residential revenue change consisted of excavation increasing 11.1%, plumbing increasing 3.3%, and drain cleaning increasing 1.3%, offset by a decline in water restoration of 6.7%.

In the second quarter of 2026, revenue from independent contractors was $17.1 million which is a decline of 1.9% as compared to the same period of 2025.

Roto-Rooter’s second quarter 2026 gross margin was 50.4%. This compares to the prior-year quarter’s gross margin of 49.0%.

2026
Q1

Q1 2026 Earnings

8-K BUY

Apr 23, 2026 · 100% conf.

AI Prediction BUY

1D

+4.46%

$400.04

Act: +10.40%

5D

+6.63%

$408.36

Act: +10.97%

20D

+7.99%

$413.56

Act: +15.30%

Price: $382.97 Prob +5D: 100% AUC: 1.000
0000019584-26-000010

EX-99

2 che-20260423xex99.htm

EX-99

Exhibit 99

CONTACT:  Michael D. Witzeman

(513) 762-6714

Chemed Reports First-Quarter 2026 Results

Full-Year Guidance Increased Due To:

·

Strong VITAS Performance

·

Re-purchase of 500,000 Shares in the Quarter

·

Two Roto-Rooter Franchises Purchased for $20.6 Million

CINCINNATI, April 23, 2026—Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS),  the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its first quarter ended March 31, 2026, versus the comparable prior-year period.

Results for Quarter Ended March 31, 2026

Consolidated operating results:

·

Revenue increased 1.6% to $657.5 million

·

GAAP Diluted Earnings-per-Share (EPS) of $4.84, a decrease of 0.4%

·

Adjusted Diluted EPS of $5.65, an increase of 0.4%

VITAS segment operating results:

·

Net Patient Revenue of $420.0 million, an increase of 3.1%

·

Average Daily Census (ADC) of 22,723, an increase of 2.2%

·

Admissions of 19,394, an increase of 6.9%

·

Net Income, excluding certain discrete items, of $52.2 million, an increase of 4.4%

·

Adjusted EBITDA, excluding Medicare Cap, of $70.8 million, an increase of 0.6%

·

Adjusted EBITDA margin, excluding Medicare Cap, of 16.8%, a decrease of 41-basis points

Roto-Rooter segment operating results:

·

Revenue of $237.5 million, a decrease of 0.9%

·

Net Income, excluding certain discrete items, of $37.7 million, a decrease of 9.7%

·

Adjusted EBITDA of $53.5 million, a decline of 9.6%

·

Adjusted EBITDA margin of 22.5%, a decline of 218-basis points

VITAS

VITAS net revenue was $420.0 million in the first quarter of 2026, which is an increase of 3.1% when compared to the prior-year period. This revenue increase is comprised primarily of a 2.2% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.6%. Acuity mix shift negatively impacted revenue growth 120-basis points in the quarter when compared to the prior-year period’s revenue and level-of-care mix.  The combination of Medicare Cap and other contra revenue changes negatively impacted revenue growth by 47-basis points.

Total VITAS admissions increased 6.9% in the first quarter of 2026 compared to the first quarter of 2025.

In the first quarter of 2026, VITAS accrued $2.4 million in Medicare Cap billing limitation.  No Medicare Cap billing limitation was recorded in the first quarter of 2026 for the Florida combined program and none is anticipated for the 2026 fiscal period.

Of VITAS’ 33 Medicare provider numbers, 25 provider numbers have an anticipated full-year Medicare Cap cushion of 10% or greater, four provider numbers have a cushion between 0% and 10%, and four provider numbers have a Medicare Cap billing limitation totaling $9.5 million.

Average revenue per patient per day in the first quarter of 2026 was $210.62 which is 146-basis points above the prior-year period. Reimbursement for routine home care and high-acuity care averaged $188.59 and $1,131.82, respectively. During the quarter, high-acuity days-of-care were 2.3% of total days of care, a decline of 28-basis points when compared to the prior-year quarter.

The first quarter 2026 gross margin, excluding Medicare Cap, was 22.9%, a 71-basis point decline from the same period of 2025. Selling, general and administrative expenses were $26.1 million in the first quarter of 2026 compared to $26.5 million in the prior-year quarter.

Adjusted EBITDA, excluding Medicare Cap, totaled $70.8 million in the quarter, an increase of 0.6% when compared to the prior-year period. Adjusted EBITDA margin in the quarter, excluding Medicare Cap, was 16.8%.

Roto-Rooter

Roto-Rooter generated quarterly revenue of $237.5 million in the first quarter of 2026, a decrease of 0.9%, when compared to the prior-year quarter.

Roto-Rooter branch commercial revenue in the quarter totaled $56.5 million, a decrease of 1.9% from the prior-year period. This aggregate commercial revenue change consisted of excavation declining 7.8%, water restoration declining 10.0% and drain cleaning declining 0.9%, offset by an increase in plumbing of 3.9%.

Roto-Rooter branch residential revenue in the quarter totaled $166.3 million, a decrease of 1.5%, over the prior-year period. This aggregate residential revenue change consisted of water restoration

declining 11.8% offset by plumbing increasing 9.3%, excavation increasing 0.9%, and drain cleaning increasing of 1.1%.

In the first quarter of 2026, revenue from independent contractors was $17.8 million which is a decline of 3.3% as compared to the same period of 2025.

Roto-Rooter’s first quarter 2026 gross margin was 51.0%. This compares to the prior-year quarter’s gross margin of 50.9%. Roto-Rooter’s selling, g

2025
Q4

Q4 2025 Earnings

8-K BUY

Feb 25, 2026 · 100% conf.

AI Prediction BUY

1D

+4.46%

$487.40

Act: -15.00%

5D

+6.63%

$497.53

Act: -11.92%

20D

+7.99%

$503.87

Price: $466.60 Prob +5D: 100% AUC: 1.000
0000019584-26-000002

che-20260225x8k

false000001958400000195842026-02-252026-02-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 25, 2026

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On February 25, 2026, Chemed Corporation issued a press release announcing its financial results for the quarter ended December 31, 2025. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated December 31, 2025

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   February 25, 2026

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Executive Vice President and Chief Financial Officer

Page 3 of 3

2025
Q3

Q3 2025 Earnings

8-K

Oct 28, 2025

0000019584-25-000004

che-20251028x8k

false000001958400000195842025-10-282025-10-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 28, 2025

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On October 28, 2025, Chemed Corporation issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated September 30, 2025

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   October 28, 2025

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Executive Vice President and Chief Financial Officer

Page 3 of 3

2025
Q2

Q2 2025 Earnings

8-K

Jul 29, 2025

0001562762-25-000181

che-20250729x8k

false000001958400000195842025-07-292025-07-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 29, 2025

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On July 29, 2025, Chemed Corporation issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the release is furnished herewith as Exhibit 99.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors: Appointment of Certain Officers, Compensatory Arrangements of Certain Officers.

(b) Nicholas M. Westfall, Executive Vice President of Chemed Corporation (the “Company”) and Chairman and Chief Executive Officer of Vitas, advised that he is resigning as Chairman and Chief Executive Officer of Vitas effective as of July 29, 2025, to pursue other interests. He will continue as Executive Vice President of Chemed and will assist with the transition of his duties until December 1, 2025. A copy of the press release announcing the events described above is attached hereto as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated June 30, 2025

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   July 29, 2025

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Executive Vice President and Chief Financial Officer

Page 3 of 3

2025
Q1

Q1 2025 Earnings

8-K

Apr 23, 2025

0001562762-25-000088

che-20250423x8k

false000001958400000195842025-04-232025-04-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 23, 2025

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On April 23, 2025, Chemed Corporation issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated April 23, 2025

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   April 23, 2025

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Chief Financial Officer

Page 3 of 3

2024
Q4

Q4 2024 Earnings

8-K

Feb 26, 2025

0001562762-25-000032

che-20250226x8k

false000001958400000195842025-02-262025-02-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 26, 2025

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On February 26, 2025, Chemed Corporation issued a press release announcing its financial results for the quarter ended December 31, 2024. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated February 26, 2025

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   February 26, 2025

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Chief Financial Officer

Page 3 of 3

2024
Q3

Q3 2024 Earnings

8-K

Oct 29, 2024

0001562762-24-000241

che-20241029x8k

false000001958400000195842024-10-292024-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 29, 2024

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On October 29, 2024, Chemed Corporation issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated October 29, 2024

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   October 29, 2024

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Chief Financial Officer

Page 3 of 3

2024
Q2

Q2 2024 Earnings

8-K

Jul 24, 2024

0001562762-24-000179

che-20240724x8k

false000001958400000195842024-07-242024-07-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 24, 2024

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On July 24, 2024, Chemed Corporation issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated July 24, 2024

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   July 24, 2024

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Chief Financial Officer

Page 3 of 3

2024
Q1

Q1 2024 Earnings

8-K

Apr 24, 2024

0001562762-24-000096

che-20240424x8k

false000001958400000195842024-04-242024-04-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 24, 2024

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On April 24, 2024, Chemed Corporation issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated April 24, 2024

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   April 24, 2024

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Chief Financial Officer

Page 3 of 3

2023
Q4

Q4 2023 Earnings

8-K

Feb 27, 2024

0001562762-24-000036

che-20240227x8k

false000001958400000195842024-02-272024-02-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 27, 2024

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On February 27, 2024, Chemed Corporation issued a press release announcing its financial results for the quarter ended December 31, 2023. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated February 27, 2023

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   February 27, 2024

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Chief Financial Officer

Page 3 of 3

2023
Q3

Q3 2023 Earnings

8-K

Oct 25, 2023

0001562762-23-000378

che-20230930x8k

false000001958400000195842023-09-302023-09-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): September 30, 2023

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On October 25, 2023, Chemed Corporation issued a press release announcing its financial results for the quarter ended September 30, 2023. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated October 25, 2023

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   October 25, 2023

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Controller

Page 3 of 3

2023
Q2

Q2 2023 Earnings

8-K

Jul 26, 2023

0001562762-23-000290

che-20230630x8k

false000001958400000195842023-06-302023-06-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 30, 2023

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On July 26, 2023, Chemed Corporation issued a press release announcing its financial results for the quarter ended June 30, 2023. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated July 26, 2023

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   July 26, 2023

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Controller

Page 3 of 3

2023
Q1

Q1 2023 Earnings

8-K

Apr 26, 2023

0001562762-23-000174

che-20230331x8k

false000001958400000195842023-03-312023-03-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 31, 2023

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On April 26, 2023, Chemed Corporation issued a press release announcing its financial results for the quarter ended March 31, 2023. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated April 26, 2023

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   April 26, 2023

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Controller

Page 3 of 3

2022
Q4

Q4 2022 Earnings

8-K

Feb 23, 2023

0001562762-23-000053

che-20230223x8k

false000001958400000195842023-02-232023-02-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 23, 2023

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On February 23, 2023 Chemed Corporation issued a press release announcing its financial results for the quarter ended December 31, 2022. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated December 31, 2022

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   December 31, 2022

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Controller

Page 3 of 3

2022
Q3

Q3 2022 Earnings

8-K

Oct 31, 2022

0001562762-22-000404

che-20221031x8k

false000001958400000195842022-10-312022-10-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 31, 2022

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On October 31, 2022 Chemed Corporation issued a press release announcing its financial results for the quarter ended September 30, 2022. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated October 31, 2022

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   October 31, 2022

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Controller

Page 3 of 3

2022
Q2

Q2 2022 Earnings

8-K

Jul 27, 2022

0001562762-22-000302

che-20220727x8k

false000001958400000195842022-07-272022-07-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 27, 2022

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On July 27, 2022 Chemed Corporation issued a press release announcing its financial results for the quarter ended June 30, 2022. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated July 27, 2022

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   July 27, 2022

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Controller

Page 3 of 3

2022
Q1

Q1 2022 Earnings

8-K

Apr 26, 2022

0001562762-22-000191

che-20220426x8k

false000001958400000195842022-04-262022-04-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 26, 2022

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On April 26, 2022 Chemed Corporation issued a press release announcing its financial results for the quarter ended March 31, 2022. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated April 26, 2022

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   April 26, 2022

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Controller

Page 3 of 3

2021
Q4

Q4 2021 Earnings

8-K

Feb 24, 2022

0001562762-22-000054

che-20220224x8k

false000001958400000195842022-02-242022-02-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): February 24, 2022

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On February 24, 2022 Chemed Corporation issued a press release announcing its financial results for the quarter ended December 31, 2021. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated February 24, 2022

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   February 24, 2022

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Controller

Page 3 of 3

2021
Q3

Q3 2021 Earnings

8-K

Oct 28, 2021

0001562762-21-000377

che-20211028x8k

false000001958400000195842021-10-282021-10-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 28, 2021

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 1-8351 31-0791746

(State or other ‎jurisdiction of ‎incorporation) (Commission File Number) (I.R.S. Employer ‎Identification ‎Number)

2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (513) 762-6690

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

[_]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_]      Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_]      Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to 12(b) of the Act:

Title of each class

Trading symbol Name of each exchange on which registered

Capital stock $1 par value CHE

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

Page 1 of 3

Item 2.02 Results of Operations and Financial Condition

On October 28, 2021 Chemed Corporation issued a press release announcing its financial results for the quarter ended September 30, 2021. A copy of the release is furnished herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

d) Exhibit

(99) Registrant’s press release dated October 28, 2021

104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL

Page 2 of 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHEMED CORPORATION

Dated:   October 28, 2021

By: /s/ Michael D. Witzeman

Michael D. Witzeman

Vice President and Controller

Page 3 of 3

Share on Social Networks: